Unique pulmonary antigen presentation may call for an alternative approach for lung cancer immunotherapy

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Chang, Stephanie ^a   Lin, Xue ^a   Higashikubo, Ryuji ^a   Toth, Kelsey ^a   Gelman, Andrew E ^a   Kreisel, Daniel ^a   Krupnick, Alexander S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immune system; Immunotherapy; Lung cancer; Mucosal antigen presentation; Natural killer cells

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; LIPOSOME; MELAN A; MELANOMA ANTIGEN 3; MUCIN 1; NY ESO 1 ANTIGEN; SIPULEUCEL T; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

EID: 84886944447     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23563     Document Type: Article

References (30)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with report of ten original cases. Am J Med Sci 1893; 105:487-511; DOI: 10.1097/00000441-189305000-00001.
2. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25:587-617; PMID: 17378764; DOI: 10.1146/annurev.immunol.25.022106.141553.
3. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95:1-30; PMID: 16860654; DOI: 10.1016/S0065-230X(06)95001-5.
4. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24:3038-43; PMID: 7805731; DOI: 10.1002/eji.1830241218.
5. Chang GY, Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, Lee PP. Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med 2011; 9:122; PMID: 21794122; DOI: 10.1186/1479-5876-9-122.
6. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID: 21498393; DOI: 10.1158/1078-0432.CCR-11-0116.
7. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID: 16946036; DOI: 10.1126/science.1129003.
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID: 21830940; DOI: 10.1056/NEJMoa1103849.
9. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID: 16809734; DOI: 10.1200/JCO.2005.04.5252.
10. Kruit W, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Maio M, et al. Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). J Clin Oncol 2011; 29:abstr 8535.
11. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53:641-51; PMID: 7678777.
12. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-81; PMID: 16170175; DOI: 10.1200/JCO.2005.13.011.
13. Vansteenkiste J, Zielinski M, Liner A, Dahabre E, Esteban W, Malinowski J, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25:abs 7554.
14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363; 711-723, PMID: 20525992; DOI: 10.1056/NEJMoa1003466.
15. Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28:A7531; DOI: 10.1200/JCO.2009.21.9618.
16. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92; PMID: 3903508; DOI: 10.1056/NEJM198512053132327.
17. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID: 10430624; DOI: 10.1084/jem.190.3.355.
18. Kreisel D, Gelman AE, Higashikubo R, Lin X, Vikis HG, White JM, et al. Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res 2012; 72:4311-7; PMID: 22751136; DOI: 10.1158/0008-5472.CAN-12-0908.
19. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID: 11323675; DOI: 10.1038/35074122.
20. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID: 21873989; DOI: 10.1038/nm.2438.
21. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72; PMID: 11406550.
22. McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993; 178:889-99; PMID: 8102390; DOI: 10.1084/jem.178.3.889.
23. Makita S, Kanai T, Nemoto Y, Totsuka T, Okamoto R, Tsuchiya K, et al. Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation. J Immunol 2007; 178:4937-46; PMID: 17404275.
24. Hänninen A, Braakhuis A, Heath WR, Harrison LC. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 2001; 50:771-5; PMID: 11289041; DOI: 10.2337/diabetes.50.4.771.
25. Limmer A, Ohl J, Wingender G, Berg M, Jüngerkes F, Schumak B, et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol 2005; 35:2970-81; PMID: 16163670; DOI: 10.1002/eji.200526034.
26. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011; 121:4015-29; PMID: 21911941; DOI: 10.1172/JCI45862.
27. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19:72-85; PMID: 21251614; DOI: 10.1016/j.ccr.2010.11.011.
28. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59:1781-9; PMID: 20703455; DOI: 10.1007/s00262-010-0904-3.
29. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID: 15632206; DOI: 10.1182/blood-2004-07-2974.
30. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID: 20610543; DOI: 10.3322/caac.20073.